The combination of lenvatinib plus pembrolizumab has shown promise in a phase Ib/II clinical trial in 137 patients with various advanced solid tumours and no standard treatment options available. The objective response rate at 24 weeks (the primary objective) was highest in renal cell carcinoma (63%), endometrial cancer (52%), and melanoma (48%).
The combination was also relatively well tolerated, and the most common treatment-related adverse events were fatigue, diarrhoea, hypertension, and hypothyroidism.
In this study, the lenvatinib plus pembrolizumab combination showed promising efficacy among patients with selected solid tumours, with a manageable safety profile.
Read more in Journal of Clinical Oncology here